Window of opportunity in PsA
CorEvitas registry:
Early initiators had more severe disease & worse PROs
but if DMARD therapy initiated within 1 yr: RR=2 MDA achievement & higher reduction of CDAI
t.co/Xm9i7aiq85
Abs#1493 #ACR22 @Rheumnow
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry - ACR Meeting Abstracts
CorEvitas registry:
Early initiators had more severe disease & worse PROs
but if DMARD therapy initiated within 1 yr: RR=2 MDA achievement & higher reduction of CDAI
t.co/Xm9i7aiq85
Abs#1493 #ACR22 @Rheumnow
